Literature DB >> 2612549

Once daily nisoldipine in hypertension: cuff and ambulatory intra-arterial blood pressure.

G Brigden1, M Heber, M Caruana, A Lahiri, E B Raftery.   

Abstract

Cuff blood pressure data has suggested that the calcium channel antagonist nisoldipine has full twenty four hour efficacy. To test this, 24 h ambulatory intra-arterial blood pressure monitoring was performed on 18 untreated hypertensive subjects (12 men, 6 women) (cuff blood pressure greater than 150/95 mm Hg) before and after chronic treatment with 10-20 mg oral nisoldipine taken daily at 08.00 h. Twelve patients completed the study, six being withdrawn, four because of side-effects. After baseline intra-arterial monitoring patients were started on 10 mg nisoldipine daily. Response was assessed by cuff pressures taken 24 h after dosing at fortnightly intervals, and if not controlled (less than 150/95 or at least 10 mm Hg reduction in diastolic BP) the dose was increased to 20 mg. All patients received at least six weeks' therapy before the second intra-arterial blood pressure monitoring. There was a slight but insignificant reduction in mean daytime heart rate of 3 beats.min-1. Mean significant reduction in daytime systolic and diastolic BP was 19 mm Hg and 13 mm Hg respectively but there was no significant mean night-time reduction. By comparison 8 out of 12 patients were apparently controlled more than 24 h post dose according to cuff pressures. This study suggests that this formulation of nisoldipine does not control blood pressure over a full 24-h period, and emphasises the importance of 24 h ambulatory monitoring in assesing the efficacy of once-daily antihypertensive agents.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2612549     DOI: 10.1007/bf00562542

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Observer factors in the measurement of blood pressure.

Authors:  J WILCOX
Journal:  JAMA       Date:  1962-01-06       Impact factor: 56.272

2.  Evaluation of performance of selected devices for measuring blood pressure.

Authors:  D R Labarthe; C M Hawkins; R D Remington
Journal:  Am J Cardiol       Date:  1973-09-20       Impact factor: 2.778

3.  The use of ambulatory blood pressure monitoring to improve the accuracy and reduce the numbers of subjects in clinical trials of antihypertensive agents.

Authors:  J Conway; J Johnston; A Coats; V Somers; P Sleight
Journal:  J Hypertens       Date:  1988-02       Impact factor: 4.844

4.  New system for recording ambulatory blood pressure in man.

Authors:  M W Millar-Craig; D Hawes; J Whittington
Journal:  Med Biol Eng Comput       Date:  1978-11       Impact factor: 2.602

5.  Superiority of 24-hour measurement of blood pressure over clinic values in determining prognosis in hypertension.

Authors:  S Mann; M W Millar Craig; E B Raftery
Journal:  Clin Exp Hypertens A       Date:  1985

6.  Relationship between level of blood pressure measured casually and by portable recorders and severity of complications in essential hypertension.

Authors:  M Sokolow; D Werdegar; H K Kain; A T Hinman
Journal:  Circulation       Date:  1966-08       Impact factor: 29.690

7.  Monitoring 24-hour blood pressure in a drug trial. Evaluation of a noninvasive device.

Authors:  G Berglund; U De Faire; J Castenfors; G Andersson; M Hartford; H Liedholm; S Ljungman; T Thulin; J Wikstrand
Journal:  Hypertension       Date:  1985 Sep-Oct       Impact factor: 10.190

8.  Once daily beta-adrenoceptor blockade in hypertension: an ambulatory assessment.

Authors:  S Mann; M W Craig; V Balasubramanian; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

9.  Assessment of 'once daily' verapamil for the treatment of hypertension using ambulatory, intra-arterial blood pressure recording.

Authors:  M Caruana; M Heber; G Brigden; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Use of graded exercise testing in assessing the hypertensive patient.

Authors:  M W Millar-Craig; V Balasubramanian; S Mann; E B Raftery
Journal:  Clin Cardiol       Date:  1980-08       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.